Impax Sued by Avanir Over Patent for Nuedexta Nerve Drug

Impax Laboratories Inc. (IPXL) was sued by Avanir Pharmaceuticals Inc. (AVNR) for allegedly infringing a new patent for the drug Nuedexta, used to control abnormal emotional outbursts.

Lawyers for Avanir contend Impax wrongly plans to market a generic version of the drug, for which a patent was awarded in July, before the patent expires in 2023, according to a complaint filed today in federal court in Wilmington, Delaware.

“Impax’s proposed product is especially adapted for a use that infringes the patent,” Avanir contends in court papers, saying there is “no substantial non-infringing use” for the product.

Avanir, based in Aliso Viejo, California, is asking a judge to rule that the patent is infringed, to order Hayward, California-based Impax not to use the technology and to award unspecified damages.

Reached by telephone, Impax spokesman Mark Donohue declined to comment on the lawsuit.

Avanir reported about $32 million in revenue for the year ending on June 30, according to data compiled by Bloomberg. Impax reported about $573 million in the same period.

The case is Avanir v. Impax, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 8,227,484.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.